IL10 and neoplasm: Generally, the immune systems of tumor patients often have excessive inhibitory functions, which are induced by regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), or the secretion of immunosuppressive cytokines, such as tumor growth factor-β (TGF-β) and interleukin-10 (IL-10).